IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents
September 19, 2023 08:03 ET
|
IN8bio, Inc
Newly granted patents expand the use of the DeltEx Drug Resistant Immunotherapy (DRI) platform to encompass Chimeric Antigen Receptor T-cell (CAR-T) and checkpoint inhibitors (CPIs).Broadens IN8bio’s...
IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
IN8bio, Inc
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
August 15, 2023 08:00 ET
|
IN8bio, Inc
NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced...
IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 16:15 ET
|
IN8bio, Inc
Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated patients (n=8) have exceeded historical...
IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility
August 08, 2023 08:00 ET
|
IN8bio, Inc
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell therapiesThe new site supports...
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting
June 05, 2023 08:00 ET
|
IN8bio, Inc
100% of treated patients (n=8) to date have exceeded historical median progression-free survival, with two patients that received three doses remaining progression-free at 23.5 and 19.4 months,...
IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
May 17, 2023 08:00 ET
|
IN8bio, Inc
Preclinical results showcase the potential for the strong synergistic combination of chemotherapy and gamma-delta T cell therapy to target solid tumors beyond the brain The DeltEx platform is the...
IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 12, 2023 08:00 ET
|
IN8bio, Inc
Presented positive INB-100 data showing long-term complete remissions (CR) and elevated gamma-delta T cell levels in 100% of evaluable treated leukemia patients; Dose Level 2 selected as the...
IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting
May 02, 2023 17:08 ET
|
IN8bio, Inc
Preclinical data demonstrates that gamma-delta T cells have the ability to target other solid tumors such as ovarian cancer, supporting the development of these technologies outside of brain tumorsThe...
IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors
May 01, 2023 08:00 ET
|
IN8bio, Inc
Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group, supporting and advancing 31 clinical assets in Eli Lilly’s oncology portfolioHe is a...